Immedica

Immedica

Immedica at a glance

Immedica is a leading European specialty pharma commercialisation and distribution platform focused on orphan and highly niched indications with high unmet medical needs.

Immedica serves patients in more than 50 countries, with capabilities covering marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory and medical affairs as well as market access.

Immedica facts

Sector

Pharmaceuticals

Impilo entry date

May 2018

HQ

Stockholm, Sweden

Management team

Anders Edvell (CEO)
Simon Falk (CFO)

Impilo team

Magnus Edlund
Fredrik Odin
Edvard Hubendick

No of FTEs

180

Revenue, EURm

2023
2024
2025

Adj. EBITDA, EURm

2023
2024
2025

Investment thesis

  • Launch and commercialisation of rare disease drugs in the EU and ME is a highly attractive and sustainable business
  • Potential to expand into a leading pan-European position in a market with high barriers to entry
  • Clear opportunity to multiply size by pursuing an active business development agenda, spanning distribution, in-licensing deals and acquisitions

UN SDG Goals